Overview

Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) Patients

Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
The primary aim is to evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in TD2M Patients
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Treatments:
Glipizide
Metformin